



Lifetime prevalence of cervical cancer screening in
55 low- and middle-income countries
Lemp, Julia M; De Neve, Jan-Walter; Bussmann, Hermann; Chen, Simiao; Manne-Goehler,
Jennifer; Theilmann, Michaela; Marcus, Maja-Emilia; Ebert, Cara; Probst, Charlotte;
Tsabedze-Sibanyoni, Lindiwe; Sturua, Lela; Kibachio, Joseph M; Moghaddam, Sahar Saeedi;
Martins, Joao S; Houinato, Dismand; Houehanou, Corine; Gurung, Mongal S; Gathecha,




None: All rights reserved
Document Version
Peer reviewed version
Citation for published version (Harvard):
Lemp, JM, De Neve, J-W, Bussmann, H, Chen, S, Manne-Goehler, J, Theilmann, M, Marcus, M-E, Ebert, C,
Probst, C, Tsabedze-Sibanyoni, L, Sturua, L, Kibachio, JM, Moghaddam, SS, Martins, JS, Houinato, D,
Houehanou, C, Gurung, MS, Gathecha, G, Farzadfar, F, Dryden-Peterson, S, Davies, JI, Atun, R, Vollmer, S,
Bärnighausen, T & Geldsetzer, P 2020, 'Lifetime prevalence of cervical cancer screening in 55 low- and middle-
income countries', JAMA The Journal of the American Medical Association, vol. 324, no. 15, pp. 1532-1542.
https://doi.org/10.1001/jama.2020.16244
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
This document is the Author Accepted Manuscript version of a published work which appears in its final form in Journal of the American
Medical Association, copyright ©  2020 American Medical Association. The final Version of Record can be found at:
https://doi.org/10.1001/jama.2020.16244
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 11. May. 2021
 1
Lifetime prevalence of cervical cancer screening in 55 low- and middle-income countries 1 
 2 
Julia M. Lemp MSc1, Jan-Walter De Neve ScD1, Hermann Bussmann MD2, Simiao Chen ScD1, 3 
Jennifer Manne-Goehler MD3,4, Michaela Theilmann MA1, Maja-Emilia Marcus MA5, Cara 4 
Ebert PhD6, Charlotte Probst PhD1,7, Lindiwe Tsabedze MPH8, Lela Sturua PhD9, Joseph M. 5 
Kibachio MD10, 11, Sahar Saeedi Moghaddam MSc12, Joao S. Martins PhD13, Dismand Houinato 6 
PhD14, Corine Houehanou PhD14, Mongal S. Gurung PhD15, Gladwell Gathecha MSc10, Farshad 7 
Farzadfar MD16, Scott Dryden-Peterson MD17, Justine I. Davies MD (res)18,19, Rifat Atun FRCP3, 8 
20, Sebastian Vollmer PhD5, Till Bärnighausen MD1,3,21, Pascal Geldsetzer ScD1,22, * 9 
 10 
1 Heidelberg Institute of Global Health (HIGH), Medical Faculty and University Hospital, 11 
University of Heidelberg, Heidelberg, Germany; 12 
2 Department of Applied Tumor Biology, Institute of Pathology, Heidelberg University 13 
Hospital, Heidelberg, Germany; 14 
3 Department of Global Health and Population, Harvard T.H. Chan School of Public Health, 15 
Boston, MA, USA; 16 
4 Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical 17 
School, Boston, MA, USA; 18 
5 Department of Economics and Centre for Modern Indian Studies, University of 19 
Goettingen, Göttingen, Germany; 20 
6 RWI - Leibniz Institute for Economic Research, Essen (Berlin office), Germany; 21 
7 Institute for Mental Health Policy Research, Centre for Addiction and Mental Health 22 
(CAMH), Toronto, Ontario, Canada; 23 
8 Eswatini Ministry of Health, Mbabane, Eswatini; 24 
 2
9 Non-Communicable Disease Department, National Center for Disease Control and Public 25 
Health, Tbilisi, Georgia; 26 
10 Division of Non-Communicable Diseases, Kenya Ministry of Health, Nairobi, Kenya; 27 
11 Institute of Global Health, Faculty of Medicine, University of Geneva (UNIGE), Geneva, 28 
Switzerland; 29 
12 Endocrinology and Metabolism Research Center, Endocrinology and Metabolism 30 
Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; 31 
13 Faculty of Medicine and Health Sciences, National University of East Timor, Rua Jacinto 32 
Candido, Dili, Timor-Leste; 33 
14 Laboratory of Epidemiology of Chronic and Neurological Diseases, Faculty of Health 34 
Sciences, University of Abomey-Calavi, Cotonou, Benin; 35 
15 Health Research and Epidemiology Unit, Ministry of Health, Thimphu, Bhutan; 36 
16 Non-Communicable Diseases Research Center, Endocrinology and Metabolism 37 
Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; 38 
17 Brigham and Women’s Hospital, Boston, Massachusetts, USA; 39 
18 MRC/Wits Rural Public Health and Health Transitions Research Unit, School of Public 40 
Health, University of Witwatersrand, Johannesburg, South Africa; 41 
19 Institute of Applied Health Research, University of Birmingham, Birmingham, UK; 42 
20 Department of Global Health and Social Medicine, Harvard Medical School, Harvard 43 
University, Boston, Massachusetts, USA; 44 
21 Africa Health Research Institute, Somkhele, South Africa; 45 
22 Division of Primary Care and Population Health, Department of Medicine, Stanford 46 
University, Stanford, CA, USA 47 
 48 
 3
* Corresponding author: 49 
Pascal Geldsetzer MBChB ScD MPH 50 
Division of Primary Care and Population Health, Department of Medicine, Stanford University, 51 
Stanford, CA, USA 52 
E-mail: pgeldsetzer@stanford.edu 53 
Phone: +1 415 694 8503 54 
 55 
Word count: 2,885 56 
Date of revision: August 5th, 2020  57 
 4
Key points 58 
Question: What is the lifetime prevalence of cervical cancer screening in low- and middle-59 
income countries? 60 
Findings: In this cross-sectional study based on self-reported data collected in 55 countries 61 
between 2005 and 2018, the country-level median lifetime prevalence of cervical cancer 62 
screening was 44%, with a range of 0.3% to 97.4%.  63 
Meaning: Although there was a wide range of variation in self-reported cervical cancer screening 64 
prevalence among these countries, the findings support the need to increase the rate of screening.65 
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Importance: The World Health Organization is developing a global strategy to eliminate 66 
cervical cancer, with goals for screening prevalence among women aged 30 to 49 years. 67 
However, evidence on prevalence levels of cervical cancer screening in low- and middle-income 68 
countries (LMICs) is sparse. 69 
Objective: To determine lifetime cervical cancer screening prevalence in LMICs, and its 70 
variation across and within world regions and countries. 71 
Design, Setting, and Participants: Cross-sectional, population-based analysis of nationally 72 
representative household surveys carried out in 55 LMICs between 2005 and 2018. The median 73 
response rate across surveys was 93.8% (range, 64.0%-99.3%). The population-based sample 74 
consisted of 1,136,289 women aged 15 years or older of whom 0.6% had missing information for 75 
the survey question on cervical cancer screening. 76 
Exposures: World region, country, countries’ economic, social, and health system 77 
characteristics, and individuals’ sociodemographic characteristics. 78 
Main Outcomes and Measures: Self-report of having ever had a screening test for cervical 79 
cancer. 80 
Results: 1,129,404 women were included in the analysis of whom 542,475 were aged 30 to 49 81 
years. A country-level median of 43.6% (interquartile-range [IQR], 13.9%-77.3%; range, 0.3%-82 
97.4%) of women aged 30 to 49 self-reported to have ever been screened, with countries in Latin 83 
America and the Caribbean having the highest prevalence (country-level median, 84.6%; IQR, 84 
65.7%-91.1%; range, 11.7%-97.4%) and those in sub-Saharan Africa the lowest prevalence 85 
(country-level median, 16.9%; IQR, 3.7%-31.0%; range, 0.9%-50.8%). There was large variation 86 
in the self-reported lifetime prevalence of cervical cancer screening among countries within 87 
regions, and among countries with similar levels of per capita gross domestic product and total 88 
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health expenditure. Within countries, women who lived in rural areas, had low education, or had 89 
low household wealth were generally least likely to self-report to have ever been screened.  90 
Conclusion and Relevance: In this cross-sectional study of data collected in 55 LMICs between 91 
2005 and 2018, there was wide variation between countries in the self-reported lifetime 92 
prevalence of cervical cancer screening. However, the median prevalence was 44%, supporting 93 
the need to increase the rate of screening.  94 
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Introduction 95 
Cervical cancer was estimated to be the fourth most common cause of cancer incidence and 96 
mortality among women globally in 2018.1 Deaths due to cervical cancer are largely preventable 97 
through regular screening combined with early-stage treatment and, more recently, through 98 
vaccination against the human papillomavirus (HPV).2,3 While scaling up HPV vaccination could 99 
prevent many cases of cervical cancer in the future,4,5 HPV vaccination coverage is currently still 100 
very low in LMICs.6,7 Increasing effective screening for cervical cancer in LMICs is, thus, 101 
indispensable to achieve a rapid reduction in cervical cancer incidence and mortality. 102 
 103 
The World Health Organization (WHO) Director-General’s call for action on cervical cancer in 104 
2018 emphasized the importance of increasing cervical cancer screening in LMICs as being key 105 
to eliminating cervical cancer as a public health problem globally.8 Implementing and 106 
maintaining effective screening programs requires an in-depth understanding of current screening 107 
rates, how they are changing over time, and which population groups within countries are not 108 
reached. However, despite its importance for policy makers in LMICs and recommended use as 109 
an indicator for measuring progress towards achieving both universal health coverage and global 110 
non-communicable disease (NCD) goals,9–11 the only available international comparison of 111 
cervical cancer screening rates with nationally representative data is based on the World Health 112 
Surveys.12,13 These surveys were conducted in 2002-2003 and are, thus, at least 17 years old. 113 
 114 
In an effort to inform the design and monitoring of interventions to improve coverage with 115 
cervical cancer screening, this study aimed to determine the proportion of women aged 30 to 49 116 
years in LMICs who self-reported to have ever been screened for cervical cancer, and how these 117 





This analysis of pseudonymized data (i.e., data that could not be linked to individuals without 122 
additional information that was not available to the analysts) was considered exempt for non-123 
human subjects research by the institutional review board of the Heidelberg University Medical 124 
Faculty. 125 
 126 
Data sources 127 
We requested access to the most recent nationally representative WHO STEPwise approach to 128 
Surveillance (STEPS) survey conducted since 2005 for all countries that the World Bank 129 
categorized as low-income, lower middle-income, or upper middle-income at any time since 130 
2005.14 To be included in this study, a country must have been an LMIC (as per the World Bank 131 
categorization) at the time of the survey’s data collection. We preferred STEPS surveys because 132 
they use the same standardized questionnaire, ask about all commonly applied cervical cancer 133 
screening techniques, sample a wide age range of women, and are the official approach 134 
developed by the WHO for monitoring NCD risk factors at the population level.  135 
 136 
If an eligible STEPS dataset was not available for a country that was an LMIC at any time since 137 
2005, or we could not gain access to it, we conducted a systematic search in September 2019 138 
using the Google search engine, the International Household Survey Network (IHSN) central data 139 
catalogue, and the Global Health Data Exchange (GHDx) to identify the most recent nationally 140 
representative household survey with data on cervical cancer screening prevalence for that 141 
country (see eMethods 1 in the Supplement for details). Surveys were eligible if they were 142 
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conducted in 2005 or later, collected data on at least three ten-year-age groups older than 15 143 
years, and asked female respondents about whether they had ever been screened for cervical 144 
cancer. We excluded surveys with a response rate below 50%. The sampling strategy and 145 
response rate calculation for each survey is detailed in eMethods 2 and 3 in the Supplement. 146 
Response rate calculations were categorized according to the American Association for Public 147 
Opinion Research definitions RR1, RR2, RR5, and COOP1.15 148 
 149 
Outcome definition  150 
The outcome for the present analysis was defined as self-reporting to have ever undergone a 151 
screening test for cervical cancer or cervical precancerous lesions. The survey questions are 152 
detailed in eMethods 4 in the Supplement.  153 
 154 
Statistical analysis 155 
This analysis proceeded in four steps. First, we estimated self-reported lifetime prevalence of 156 
cervical cancer screening by country and calculated the country-level median prevalence (as well 157 
as the range and interquartile range) globally and by World Bank region. We restricted the 158 
sample for analysis to women aged 30 to 49 years in our primary analysis for this step because 159 
the WHO recommends prioritizing cervical cancer screening in this age group.16  160 
 161 
Second, to ascertain health system performance for cervical cancer screening relative to a 162 
country’s wealth and expenditure on health, we plotted the self-reported lifetime prevalence of 163 
cervical cancer screening for women aged 30 to 49 years against the country’s gross domestic 164 
product (GDP) per capita and total health expenditure per capita (both in constant 2011 165 
international dollars17) in the year of survey data collection. We show an ordinary least squares 166 
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regression line through these point estimates, weighting each country equally, for visual 167 
orientation only (as opposed to statistical inference).  168 
 169 
Third, to explore reasons for differences in screening prevalence between countries, we plotted 170 
the self-reported lifetime prevalence of cervical cancer screening for women aged 30 to 49 years 171 
separately against each of eight country-level indicators. We used all country-level indicators as 172 
independent variables that we hypothesized may be causally related to a country’s cervical cancer 173 
screening prevalence and were available in the public domain for the majority of the study 174 
countries. These indicators were measures of economic development (GDP per capita), human 175 
development (the Human Development Index [HDI] and the Gender-related Development Index 176 
[GDI]), investments into the health system (total health expenditure per capita), health worker 177 
density (number of nurses and midwives per 1,000 people and combined number of physicians, 178 
nurses, and midwives per 1,000 people), and gender discrimination (the Gender Inequality Index 179 
[GII] and the 2014 Social Institutions and Gender Index [SIGI]).  180 
 181 
Fourth, to ascertain which population groups were most likely to self-report to have ever been 182 
screened, we regressed, separately for each country, self-reporting to have ever had a cervical 183 
cancer screening test on ten-year age group, educational attainment, household wealth quintile, 184 
rural versus urban residence, and a binary indicator for current self-reported tobacco smoking. 185 
The computation of the household wealth quintiles is detailed in the Supplement (eMethods 5). 186 
We fitted covariate-unadjusted and covariate-adjusted Poisson regression models with cluster-187 
robust standard errors (using the sandwich estimator of variance) that were adjusted for clustering 188 
at the level of the primary sampling unit. We adhere to the term “risk” when interpreting the 189 
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resulting risk ratios (RRs) even though risk in this analysis depicts a desirable (reporting to have 190 
undergone screening) rather than an undesirable outcome.  191 
 192 
All analyses were complete-case analyses. All primary analyses accounted for the multi-stage 193 
random sampling of the surveys by use of sampling weights and adjusted standard errors for 194 
clustering at the level of the primary sampling unit. As a robustness check for the fourth step of 195 
this analysis and given ongoing debate as to when regression in survey data should account for 196 
sampling weights,18 we also fitted Poisson regression models without using sampling weights. 197 
We provide further details on the statistical analysis in the Supplement (eMethods 6). Analyses 198 
were conducted in R version 3.6.1 and Stata 15. 199 
 200 
Results 201 
Sample characteristics 202 
Out of a total of 142 countries that were classified as an LMIC at any point since 2005, we 203 
obtained individual-level STEPS survey data from 20 LMICs and included, from the systematic 204 
search, survey datasets from an additional 35 LMICs (eFigure 1 and eFigure 2 in the 205 
Supplement). Of the 55 included surveys, 20 surveys asked women whether they had ever 206 
undergone at least one of the three commonly used screening modalities (Pap smear test, visual 207 
inspection of the cervix with acetic acid [VIA], or HPV test), 28 surveys asked only about Pap 208 
smear tests, and seven surveys asked about cervical cancer screening without specifying a 209 
screening modality. The survey-level median response rate was 93.8% (IQR, 86.2%-96.8%; 210 
range, 64.0%-99.3%; Table 1). The country-level median percent of women aged 30 to 49 years 211 
with missing information on whether they had ever received a cervical cancer screening was 212 
0.5% (IQR, 0.1%-3.4%; range, 0.0%-12.6%). 1,129,404 women with outcome data, of whom 213 
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542,475 were aged 30 to 49 years, were included in the analyses (eTable 1 in the Supplement). 214 
Detailed sample characteristics are shown in eTable 2-4 in the Supplement. 215 
 216 
Lifetime prevalence of cervical cancer screening by region and country 217 
A country-level median of 43.6% (IQR, 13.9%-77.3%) of women aged 30 to 49 years self-218 
reported to have ever had a cervical cancer screening test, ranging from 0.3% in Egypt (95% CI, 219 
0.1%-0.6%) to 97.4% in Colombia (95% CI, 97.0%-97.8%). With a country-level median of 220 
84.6% (IQR, 65.7%-91.1%; range, 11.7%-97.4%), countries in Latin America and the Caribbean 221 
had the highest self-reported lifetime prevalence of cervical cancer screening, whereas countries 222 
in sub-Saharan Africa had the lowest (country-level median, 16.9%; IQR, 3.7%-31.0%; range, 223 
0.9%-50.8%) (Figure 1; eFigure 3-5 and eTable 5 in the Supplement). There was substantial 224 
variation across countries within regions. 225 
 226 
Benchmarking to countries’ gross domestic product and total health expenditure 227 
Both GDP per capita and total health expenditure per capita appeared to be positively associated 228 
with the self-reported lifetime prevalence of cervical cancer screening in a country (Figure 2). 229 
Countries that performed well relative to their GDP per capita in the year of the survey included 230 
Belarus, Belize, Bhutan, Bolivia, Brazil, Chile, Colombia, the Dominican Republic, Ecuador, El 231 
Salvador, Guatemala, Honduras, Jamaica, Moldova, Nicaragua, Peru, and St. Vincent and the 232 
Grenadines.  233 
 234 
Country-level variables associated with lifetime prevalence of cervical cancer screening  235 
In addition to GDP per capita and total health expenditure per capita, a higher HDI and more 236 
gender equality as indicated by the GDI, GII, and SIGI appeared to be positively associated with 237 
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a country’s lifetime prevalence of cervical cancer screening (Figure 3). A higher density of 238 
nurses and midwives, as well as of all health workers, statistically accounted for less of the 239 
variability in the self-reported lifetime prevalence of cervical cancer screening between countries 240 
(R2 = 0.05 and R2 = 0.09, respectively) than the other country-level variables. The apparent 241 
associations shown in Figure 3 were similar when using weighting to adjust for differences in 242 
individual-level characteristics between countries (eFigure 8-11 in the Supplement). 243 
 244 
Individual-level variables associated with cervical cancer screening 245 
While there was some heterogeneity among countries, living in an urban area (compared to a 246 
rural area), having had secondary or tertiary education (compared to only having completed 247 
primary education or less), being in the two highest household wealth quintiles (compared to the 248 
bottom two household wealth quintiles), and being aged 30 to 49 years (compared to 20 to 29 249 
years) all appeared to be associated with a higher probability of self-reporting to have ever had a 250 
cervical cancer screening test in most countries (Figure 4; eFigure 12-13; eTable 6-11 in the 251 
Supplement). The relationship between age and self-reported lifetime prevalence of cervical 252 
cancer screening had an inverted “U” shape in all regions, with middle-aged women having the 253 
highest self-reported prevalence (eFigure 14 in the Supplement). There was no apparent 254 
association between currently smoking (compared to having never smoked or smoked in the past) 255 
and self-reporting of ever having had a cervical cancer screening test in 32 out of 46 countries 256 
that collected smoking data (eFigure 15; eTable 12 in the Supplement). Currently being married 257 
appeared to be associated with a higher probability of self-reporting to have ever had a cervical 258 
cancer screening test in 41 out of 55 countries (eFigure 16; eTable 13 in the Supplement). Risk 259 
ratios with 95% confidence intervals from covariate-unadjusted and covariate-adjusted 260 
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regressions are shown in eTable 14-24 in the Supplement. The regression results were similar 261 
when not using sampling weights (eFigure 17-24; eTable 6-13; eTable 25-35 in the Supplement). 262 
 263 
Countries with a lower GDP per capita at the time of the survey tended to have larger relative 264 
differences in lifetime cervical cancer screening prevalence by education, household wealth, and 265 
urban versus rural residency than countries with a higher GDP per capita (eFigure 25-30 in the 266 
Supplement). This was not the case when examining absolute rather than relative differences 267 
(eFigure 25-30 in the Supplement). 268 
 269 
Discussion 270 
Overall, the country-level median lifetime prevalence of self-reported cervical cancer screening 271 
was 44% in this sample of 55 LMICs, which represent 72% of the world’s population in 272 
LMICs.19 Screening prevalence was generally highest among countries in Latin America and the 273 
Caribbean, and lowest among countries in sub-Saharan Africa. In addition, the highly populous 274 
countries of Indonesia (survey in 2014-15), India (survey in 2015-16), and China (survey in 275 
2008-10) had a comparatively low self-reported lifetime screening prevalence among women 276 
aged 30 to 49 years. Within countries, women in rural areas and those who were less educated or 277 
lived in a less wealthy household tended to be least likely to self-report having ever been 278 
screened for cervical cancer. 279 
 280 
The low prevalence of self-reported cervical cancer screening identified in this study is especially 281 
concerning given that this analysis examined lifetime prevalence of screening as opposed to the 282 
prevalence of being screened in the past three to five years as recommended by the WHO,16 the 283 
limited sensitivity of available screening tests,20,21 often poorly functioning referral systems for 284 
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positive cervical cancer screening tests in LMICs,22,23 and low quality of care for cervical cancer 285 
diagnosis and treatment in many of these settings.22,24,25 Nonetheless, while the majority of 286 
countries (37 of 55) included in this study missed the target of 70% cervical cancer screening 287 
prevalence proposed by the WHO,26 the analyses identified large differences in self-reported 288 
lifetime prevalence among regions and among countries within regions. Relative to their GDP per 289 
capita and total health expenditure per capita, many countries in Latin America and the 290 
Caribbean, as well as some countries in other regions (e.g., Belarus, Bhutan, or Moldova) 291 
achieved high self-reported lifetime prevalence levels of cervical cancer screening. Reasons for 292 
these countries’ high performance may include having national cervical cancer control programs 293 
in place that provide cervical cancer screening to women free of charge in primary healthcare 294 
system structures at the local level,27,28 integration of screening services into comprehensive 295 
cervical cancer control activities,28,29 as well as trialing and implementation of programs to reach 296 
underserved sociodemographic groups.30,31 297 
 298 
GDP per capita, total health expenditure per capita, HDI, GDI, GII, and SIGI all statistically 299 
accounted for a substantial degree of the variation in self-reported lifetime prevalence of cervical 300 
cancer screening between countries. The comparatively strong apparent association between 301 
indices of gender equality and self-reported lifetime prevalence of cervical cancer screening 302 
suggests that cultural and societal values influence women’s demand for and/or access to cervical 303 
cancer screening.32 The density of nurses and midwives, as well as the density of healthcare 304 
workers in general, statistically accounted for only relatively little (less than ten percent) of the 305 
variation between countries, suggesting that other factors may be more important determinants of 306 
screening rates, such as the distribution of healthcare workers within countries, if healthcare 307 
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workers have been trained and equipped to conduct cervical cancer screens, and whether women 308 
seek out or consent to screenings.33  309 
 310 
Limitations 311 
This study has several limitations. First, 28 of the 55 included surveys asked women only 312 
whether they had undergone a Pap smear test rather than cervical cancer screening more 313 
generally. However, available documentation on cervical cancer screening practices in these 314 
countries suggests that it is unlikely that a substantial degree of cervical cancer screening was 315 
conducted through modalities other than Pap smear testing in all but three (Guatemala, Mexico, 316 
and Nepal) of these 28 countries prior to the data collection period of the included survey (see 317 
eMethods 7 and eTable 36 in the Supplement). Nevertheless, this study’s estimates of self-318 
reported lifetime prevalence of  cervical cancer screening in these three countries may be 319 
underestimates of the true prevalence. Second, this study’s estimates relied entirely on self-report. 320 
This probably led to an overestimation of the true lifetime cervical cancer screening prevalence 321 
because it is likely that most women who had a cervical cancer screening remember the event 322 
(given that these screenings are generally perceived as being uncomfortable34,35), while some 323 
women who did not have a screening in the past probably reported having had one due to social 324 
desirability bias.36 However, because the awareness of the recommendation to have a regular 325 
screening, and thus the expected degree of bias from social desirability bias, is fairly low in 326 
LMICs,37,38 it is unlikely that social desirability bias led to a substantial overestimation of self-327 
reported cervical cancer screening prevalence in this study. Third, the surveys were conducted in 328 
different years ranging from 2005 to 2018. Each country’s performance should thus be 329 
interpreted as the performance in the given year rather than as the country’s current performance. 330 
Under the assumption that cervical cancer screening prevalence has been increasing in LMICs 331 
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over time, this study likely underestimates the current prevalence of cervical cancer screening in 332 
the study countries. To avoid confounding by time in the analyses with country-level independent 333 
variables, this analysis used values for country-level variables for the year of the survey’s data 334 
collection. This, however, was not possible for the SIGI, for which values were only available for 335 
2014 and 2019. Fourth, the 55 LMICs in this analysis are unlikely to be representative of all 336 
LMICs globally.  337 
 338 
Conclusions 339 
In this cross-sectional study of data collected in 55 LMICs between 2005 and 2018, there was 340 
wide variation between countries in the self-reported lifetime prevalence of cervical cancer 341 
screening. However, the median prevalence was 44%, supporting the need to increase the rate of 342 
screening. 343 
 344 
Acknowledgments: We would like to thank each of the survey teams and study participants who 345 
made this analysis possible. 346 
 347 
Conflict of Interest Disclosures: SD-P has received personal fees from UpToDate, Inc. for work 348 
unrelated to this manuscript. All other authors declare no conflicts of interest. 349 
 350 
Funding/Support: PG was supported by the National Center for Advancing Translational 351 
Sciences of the National Institutes of Health under Award Number KL2TR003143. J-WDN was 352 
supported by the Alexander von Humboldt Foundation. 353 
 354 
 18
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; 355 
analysis and interpretation of the data; preparation, review, or approval of the manuscript; or 356 
decision to submit the manuscript for publication. 357 
 358 
Access to Data and Data Analysis: JL and PG had full access to all the data in the study and 359 
take responsibility for the integrity of the data and the accuracy of the data analysis. 360 
 361 
References 362 
1.  Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 363 
2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 364 
countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492 365 
2.  Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R. Screening for cervical cancer: a 366 
systematic review and meta-analysis. Syst Rev. 2013;2(1):35. doi:10.1186/2046-4053-2-35 367 
3.  Campos NG, Sharma M, Clark A, et al. The health and economic impact of scaling 368 
cervical cancer prevention in 50 low- and lower-middle-income countries. Int J Gynecol 369 
Obstet. 2017;138:47-56. doi:10.1002/ijgo.12184 370 
4.  Huh WK, Joura EA, Giuliano AR, et al. Final efficacy, immunogenicity, and safety 371 
analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a 372 
randomised, double-blind trial. Lancet. 2017;390(10108):2143-2159. doi:10.1016/S0140-373 
6736(17)31821-4 374 
5.  Brisson M, Kim JJ, Canfell K, et al. Impact of HPV vaccination and cervical screening on 375 
cervical cancer elimination: a comparative modelling analysis in 78 low-income and 376 
lower-middle-income countries. Lancet. 2020;395(10224):575-590. doi:10.1016/S0140-377 
6736(20)30068-4 378 
 19
6.  Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus 379 
vaccination coverage by region and income level: A pooled analysis. Lancet Glob Heal. 380 
2016;4(7):e453-e463. doi:10.1016/S2214-109X(16)30099-7 381 
7.  Oberlin AM, Rahangdale L, Chinula L, Fuseini NM, Chibwesha CJ. Making HPV 382 
vaccination available to girls everywhere. Int J Gynecol Obstet. 2018;143(3):267-276. 383 
doi:10.1002/ijgo.12656 384 
8.  Adhanom Ghebreyesus T. Cervical Cancer: An NCD We Can Overcome. 385 
https://www.who.int/reproductivehealth/DG_Call-to-Action.pdf. Published 2018. 386 
Accessed October 23, 2019. 387 
9.  Wagstaff A, Neelsen S. A comprehensive assessment of universal health coverage in 111 388 
countries: a retrospective observational study. Lancet Glob Heal. 2020;8(1):e39-e49. 389 
doi:10.1016/S2214-109X(19)30463-2 390 
10.  Hogan DR, Stevens GA, Hosseinpoor AR, Boerma T. Monitoring universal health 391 
coverage within the Sustainable Development Goals: development and baseline data for an 392 
index of essential health services. Lancet Glob Heal. 2018;6(2):e152-e168. 393 
doi:10.1016/S2214-109X(17)30472-2 394 
11.  World Health Organization. Noncommunicable Diseases Global Monitoring Framework: 395 
Indicator Definitions and Specifications.; 2013. https://www.who.int/nmh/ncd-396 
tools/indicators/GMF_Indicator_Definitions_Version_NOV2014.pdf. 397 
12.  Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 398 
countries: Low average levels and large inequalities. PLoS Med. 2008;5(6):0863-0868. 399 
doi:10.1371/journal.pmed.0050132 400 
13.  Akinyemiju TF. Socio-Economic and Health Access Determinants of Breast and Cervical 401 
Cancer Screening in Low-Income Countries: Analysis of the World Health Survey. Noor 402 
 20
AM, ed. PLoS One. 2012;7(11):e48834. doi:10.1371/journal.pone.0048834 403 
14.  The World Bank. Historical classification by income. World Bank Country and Lending 404 
Groups. http://databank.worldbank.org/data/download/site-content/OGHIST.xls. Published 405 
2020. Accessed May 23, 2020. 406 
15.  The American Association for Public Opinion Research. Standard Definitions: Final 407 
Dispositions of Case Codes and Outcome Rates for Surveys. 9th edition. AAPOR. 408 
https://www.aapor.org/AAPOR_Main/media/publications/Standard-409 
Definitions20169theditionfinal.pdf. Published 2016. Accessed April 14, 2020. 410 
16.  World Health Organization. WHO guidelines for screening and treatment of precancerous 411 
lesions for cervical cancer prevention. 412 
https://apps.who.int/iris/bitstream/handle/10665/94830/9789241548694_eng.pdf. 413 
Published 2013. Accessed October 23, 2019. 414 
17.  The World Bank. GDP per capita, PPP (constant 2011 international $). 415 
https://data.worldbank.org/indicator/NY.GDP.PCAP.PP.KD. Published 2019. Accessed 416 
October 23, 2019. 417 
18.  Deaton A. Econometric issues for survey data. In: The Analysis of Household Surveys 418 
(Reissue Edition with a New Preface): A Microeconometric Approach to Development 419 
Policy. The World Bank; 2019:63-132. doi:10.1596/978-1-4648-1331-3_ch2 420 
19.  UN Department of Economic and Social Affairs. World Population Prospects 2019. 421 
https://population.un.org/wpp/Download/Standard/Population/. Published 2019. Accessed 422 
October 23, 2019. 423 
20.  Fokom-Domgue J, Combescure C, Fokom-Defo V, et al. Performance of alternative 424 
strategies for primary cervical cancer screening in sub-Saharan Africa: systematic review 425 
and meta-analysis of diagnostic test accuracy studies. BMJ. July 2015:h3084. 426 
 21
doi:10.1136/bmj.h3084 427 
21.  Chen C, Yang Z, Li Z, Li L. Accuracy of Several Cervical Screening Strategies for Early 428 
Detection of Cervical Cancer: A Meta-Analysis. Int J Gynecol Cancer. 2012;22(6):908-429 
921. doi:10.1097/IGC.0b013e318256e5e4 430 
22.  Maza M, Schocken CM, Bergman KL, Randall TC, Cremer ML. Cervical Precancer 431 
Treatment in Low- and Middle-Income Countries: A Technology Overview. J Glob Oncol. 432 
2017;3(4):400-408. doi:10.1200/JGO.2016.003731 433 
23.  Maza M, Matesanz S, Alfaro K, et al. Adherence to recommended follow-up care after 434 
high-grade cytology in El Salvador. Int J Healthc. 2016;2(2). doi:10.5430/ijh.v2n2p31 435 
24.  Drummond JL, Were MC, Arrossi S, Wools-Kaloustian K. Cervical cancer data and data 436 
systems in limited-resource settings: Challenges and opportunities. Int J Gynecol Obstet. 437 
2017;138:33-40. doi:10.1002/ijgo.12192 438 
25.  Catarino R, Petignat P, Dongui G, Vassilakos P. Cervical cancer screening in developing 439 
countries at a crossroad: Emerging technologies and policy choices. World J Clin Oncol. 440 
2015;6(6):281-290. doi:10.5306/wjco.v6.i6.281 441 
26.  World Health Organization. Draft Global Strategy towards the Elimination of Cervical 442 
Cancer as a Public Health Problem.; 2019. https://www.who.int/docs/default-443 
source/cervical-cancer/cerv-cancer-elimn-strategy-16dec-12pm.pdf. Accessed January 15, 444 
2020. 445 
27.  Dhendup T, Tshering P. Cervical cancer knowledge and screening behaviors among 446 
female university graduates of year 2012 attending national graduate orientation program, 447 
Bhutan. BMC Womens Health. 2014;14(1):44. doi:10.1186/1472-6874-14-44 448 
28.  International Agency for Research on Cancer. Current Status and Future Directions of 449 
Breast and Cervical Cancer Prevention and Early Detection in Belarus. IARC Working 450 
 22
Group Report Volume 6. 451 
https://publications.iarc.fr/_publications/media/download/4048/987fae663fb0fde0b9f3124452 
5163bba6e7f2051cb.pdf. Published 2012. Accessed October 30, 2019. 453 
29.  United Nations Population Fund (UNFPA). Cervical Cancer Prevention Project in the 454 
Republic of Moldova. https://moldova.unfpa.org/en/publications/cervical-cancer-455 
prevention-project-republic-moldova. Published 2017. Accessed October 30, 2019. 456 
30.  Maza M, Alfaro K, Garai J, et al. Cervical cancer prevention in El Salvador (CAPE)—An 457 
HPV testing-based demonstration project: Changing the secondary prevention paradigm in 458 
a lower middle-income country. Gynecol Oncol Reports. 2017;20:58-61. 459 
doi:10.1016/j.gore.2017.02.011 460 
31.  Baussano I, Tshering S, Choden T, et al. Cervical cancer screening in rural Bhutan with 461 
the care HPV test on self-collected samples: an ongoing cross-sectional, population-based 462 
study (REACH-Bhutan). BMJ Open. 2017;7(7):e016309. doi:10.1136/bmjopen-2017-463 
016309 464 
32.  Williams-Brennan L, Gastaldo D, Cole DC, Paszat L. Social determinants of health 465 
associated with cervical cancer screening among women living in developing countries: A 466 
scoping review. Arch Gynecol Obstet. 2012;286(6):1487-1505. doi:10.1007/s00404-012-467 
2575-0 468 
33.  Maseko FC, Chirwa ML, Muula AS. Health systems challenges in cervical cancer 469 
prevention program in Malawi. Glob Health Action. 2015;8(1):26282. 470 
doi:10.3402/gha.v8.26282 471 
34.  Chorley AJ, Marlow LA V., Forster AS, Haddrell JB, Waller J. Experiences of cervical 472 
screening and barriers to participation in the context of an organised programme: a 473 
systematic review and thematic synthesis. Psychooncology. 2017;26(2):161-172. 474 
 23
doi:10.1002/pon.4126 475 
35.  Armstrong N, James V, Dixon-Woods M. The role of primary care professionals in 476 
women’s experiences of cervical cancer screening: a qualitative study. Fam Pract. 477 
2012;29(4):462-466. doi:10.1093/fampra/cmr105 478 
36.  Lavrakas P, ed. Social Desirability. In: Encyclopedia of Survey Research Methods. 2455 479 
Teller Road, Thousand Oaks California 91320 United States of America: Sage 480 
Publications, Inc. doi:10.4135/9781412963947.n537 481 
37.  Chidyaonga-Maseko F, Chirwa ML, Muula AS. Underutilization of cervical cancer 482 
prevention services in low and middle income countries: a review of contributing factors. 483 
Pan Afr Med J. 2015;21. doi:10.11604/pamj.2015.21.231.6350 484 
38.  Devarapalli P, Labani S, Nagarjuna N, Panchal P, Asthana S. Barriers affecting uptake of 485 
cervical cancer screening in low and middle income countries: A systematic review. Indian 486 
J Cancer. 2018;55(4):318. doi:10.4103/ijc.IJC_253_18 487 
39.  ICF. Demographic and Health Surveys (various) [Bolivia, Colombia, Cote d’Ivoire, 488 
Dominican Republic, Egypt, Guatemala, Haiti, Honduras, India, Lesotho, Namibia, Peru, 489 
Philippines, South Africa, Sri Lanka, Zimbabwe]. Funded by USAID. 490 
https://dhsprogram.com/. 491 
40.  UNHCR. Syria Regional Refugee Response. Operational Portal Refugees Situations. 492 
https://data2.unhcr.org/en/situations/syria/location/71. Published 2019. Accessed October 493 
23, 2020. 494 
 495 
  496 
 24
Figure 1. Self-reported lifetime prevalence of cervical cancer screening among women 497 
aged 30 to 49 years, by country 498 
Abbreviations: LMIC, low- or middle-income country at the time of the survey year 499 
The numbers show the percent of women aged 30 to 49 years in each country who reported to have ever had a cervical cancer 500 
screening test. Solid grey coloring indicates that there was no eligible survey or we could not obtain access to the dataset. 501 
Prevalence estimates are shown for the countries and survey years listed in Table 1. A map with aged-standardized estimates based 502 





Figure 2. Self-reported lifetime prevalence of cervical cancer screening among women 508 
aged 30 to 49 years by GDP per capita and total health expenditure per capita 509 
Abbreviations: S. Asia, E. Asia, & Pacific, South Asia, East Asia, and Pacific. 510 
Countries are indicated by their ISO 3 code. GDP per capita and total health expenditure per capita is in constant 2011 international 511 
dollars for the year in which each survey was conducted. Health expenditure per capita was not available for Iraq. The vertical bars 512 
depict the 95% confidence interval for each point estimate. The grey line depicts an Ordinary Least Squares regression (with each 513 
country having the same weight) of lifetime cervical cancer screening prevalence in a country onto GDP per capita or total health 514 
expenditure per capita. The standardized regression coefficient for this Ordinary Least Squares regression was 0.47 (95% CI, 0.23-515 
0.71) and 0.49 (95% CI, 0.25-0.73), respectively. The sample was restricted to women aged 30 to 49 years. Estimates among all 516 
women and estimates adjusted for differences in individual-level characteristics between countries are shown in eFigure 6, 8 and 10 517 





Figure 3. Self-reported lifetime prevalence of cervical cancer screening among women 523 
aged 30 to 49 years by human development index, gender equality indices, and health 524 
worker density 525 
Abbreviations: S. Asia, E. Asia, & Pacific, South Asia, East Asia, and Pacific. 526 
Countries are indicated by their ISO 3 code. A GDI value was not available for St. Vincent & the Grenadines. A GII value was not 527 
available for Ghana, St. Vincent & the Grenadines, and Timor-Leste. The vertical bars depict the 95% confidence interval for each 528 
point estimate. Each grey line depicts an Ordinary Least Squares regression (with each country having the same weight) of lifetime 529 
cervical cancer screening prevalence in a country onto the country-level variables HDI, GDI, GII, SIGI, density of medical nurses and 530 
midwives, and health worker density. The standardized regression coefficient for this Ordinary Least Squares regression was 0.53 531 
(95% CI, 0.30-0.76), 0.62 (95% CI, 0.41-0.83), -0.40 (95% CI, -0.66- -0.15), -0.72 (95% CI, -0.92- -0.52), 0.24 (95% CI, -0.02-0.50), 532 
0.22 (95% CI, -0.04-0.48), and 0.30 (95% CI, 0.04-0.56), respectively. The sample was restricted to women aged 30 to 49 years. 533 
Estimates among all women and estimates adjusted for differences in individual-level characteristics between countries are shown in 534 





Figure 4. Relative and absolute differences in the probability of having ever been 540 
screened for cervical cancer by individuals’ sociodemographic characteristics 541 
Abbreviations: ref., reference category 542 
Risk ratios are shown on a logarithmic scale. Countries are indicated by their ISO 3 code. Except for panel D, regressions were 543 
adjusted for age as a continuous variable with restricted cubic splines with five knots placed at the fifth, 27.5th, 50th, 72.5th and 95th 544 
percentiles. All regressions were run separately for each country, used sampling weights, and adjusted standard errors for clustering 545 
at the level of the primary sampling unit. The horizontal bars depict the 95% confidence interval for each point estimate. In panel C, 546 
the upper limit of the confidence interval was truncated for the risk ratio in Cote d’Ivoire. An alternative panel C that compares top 547 
20% versus bottom 20% wealth (instead of top 40% versus bottom 40%) is shown in eFigure 11 in the Supplement. Risk ratios from 548 
Poisson regressions without using sampling weights are shown eFigure 15-22 in the Supplement. Exact estimates are provided in 549 
eTable 6-12 in the Supplement.550 
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Table 1. Survey characteristics by region and countrya,b 
Country ISO 
code 
























in 2019g  
(thousands) 
Latin America and the Caribbean 
Belize BLZ CAMDI 2005-6 92.7 0.8 1,425 19-94 562 40 7,924 196 
Costa Rica CRI ENSA 2006 95.0 12.1 2,474 18-101 772 40 11,558 2,525 
Bolivia BOL DHS 2008 95.9 0.6 16,699 15-49 7,782 38 5,525 5,733 
El Salvador SLV FESAL 2008 90.0 0.2 11,983 15-49 6,094 37 6,309 3,430 
Jamaica JAM RHS 2008 96.7 0.5 8,217 15-49 4,532 39 8,593 1,485 
Paraguay PRY ENDSSR 2008 95.1 0.1 6,536 15-44 2,666 36 9,028 3,464 
Chile CHL ENS 2009-10 85.0 7.2 2,916 15-100 1,036 40 18,924 9,610 
Nicaragua NIC ENDESA 2011 93.8 0.1 15,257 15-49 7,183 37 4,163 3,320 
Honduras HND DHS 2011-12 93.2 0.0 22,019 15-49 9,677 38 4,028 4,877 
Argentina ARG ENFR 2013 70.7 0.5 17,951 18-98 6,891 38 19,638 22,939 
Brazil BRA PNS 2013 77.0 0.0 34,282 18-101 14,546 38 15,062 107,316 
Dominican 
Republic 
DOM DHS 2013 94.1 0.4 8,990 15-49 4,347 39 12,183 5,373 
Ecuador ECU ENSANUT 2012 NA 0.2 17,808 15-50 10,121 38 10,286 8,683 




VCT STEPS 2013 67.8 0.2 1,937 18-69 902 39 10,259 54 
Mexico MEX SAGE 2014 81.0 0.0 2,799 18-98 368 40 17,150 65,172 
Guatemala GTM DHS 2014-15 96.8 0.1 25,557 15-49 11,224 38 7,220 8,922 
Colombia COL DHS 2015 86.6 0.0 26,670 21-49 17,235 38 13,115 25,626 
Guyana GUY STEPS 2016 66.7 0.1 1,588 18-69 690 39 7,285 390 
Haiti HTI DHS 2016-17 99.3 0.0 2,495 35-64 1,368 41 1,654 5,705 
Europe and Central Asia 
Russia RUS SAGE 2007-10 87.7 1.0 2,777 19-99 215 41 23,063 78,269 
Kyrgyzstan KGZ STEPS 2013 NA 0.7 1,665 25-64 840 40 3,117 3,242 
Moldova MDA STEPS 2013 83.5 11.5 2,637 18-69 939 39 5,638 2,105 
Bulgaria BGR EHS 2014 72.5 13.4 2,897 15-85 802 40 16,324 3,600 
Romania ROU EHS 2014 NA 0.0 8,728 15-85 2,616 40 19,802 9,946 
Georgia GEO STEPS 2016 75.7 1.3 2,903 17-70 1,000 40 9,256 2,091 
Belarus BLR STEPS 2016-17 87.1 7.8 2,692 18-69 1,095 41 16,978 5,052 
Azerbaijan AZE STEPS 2017 97.3 5.1 1,580 18-69 632 40 15,929 5,032 
Tajikistan TJK STEPS 2016-17 94.4 4.9 1,539 18-70 773 39 2,854 4,623 
Mongolia MNG SISS 2018 92.0 0.3 10,765 15-49 6,764 39 12,209 1,635 
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Middle East and Northern Africa 
Egypt EGY DHS 2015 98.9 0.0 8,687 15-59 3,653 38 10,243 49,665 
Iraq IRQ STEPS 2015 98.8 4.0 2,355 18-102 1,148 39 14,964 19,418 
Algeria DZA STEPS 2016-17 93.2 2.1 3,823 18-69 1,928 39 13,908 21,303 
Iran IRN STEPS 2016 98.4 4.5 15,260 18-100 6,712 38 18,664 41,024 
Lebanon LBN STEPS 2017 69.9 8.2 2,167 16-70 1,022 39 11,647 3,911 h 
Morocco MAR STEPS 2017 89.0 4.0 3,398 18-100 1,535 39 7,509 18,379 
South Asia, East Asia, and Pacific 
China CHN SAGE 2008-10 98.9 5.2 7,601 18-93 785 42 8,683 698,159 
Philippines PHL DHS 2013 98.3 0.0 24,832 15-49 12,269 39 6,282 53,801 
Bhutan BTN STEPS 2014 96.9 1.9 1,712 18-69 887 38 7,954 358 
Nepal NPL SOSAS 2014 97.0 2.0 1,007 15-100 394 38 2,385 15,562 
Timor-
Leste 
TLS STEPS 2014 96.3 7.8 1,407 18-69 668 39 6,467 640 
Indonesia IDN IFLS 2014-15 90.5 0.0 16,518 15-101 7,151 37 10,181 134,356 
India IND DHS 2015-16 96.7 0.0 677,463 15-49 331,512 38 5,944 656,288 
Sri Lanka LKA DHS 2016 98.9 0.1 18,288 15-49 13,968 39 11,447 11,090 
            
Sub-Saharan Africa 
Ghana GHA SAGE 2008-09 92.1 12.4 2,407 18-114 294 40 2,729 15,002 
Cote 
d'Ivoire 
CIV DHS 2011-12 93.0 0.3 9,802 15-49 4,130 37 5,192 12,742 
Namibia NAM DHS 2013 93.8 0.9 9,641 15-64 3,969 38 9,600 1,286 
Botswana BWA STEPS 2014 64.0 2.3 2,687 15-69 1125 38 16,175 1,190 
Eswatini SWZ STEPS 2014 81.8 7.3 2,135 15-70 821 38 9,309 585 
Lesotho LSO DHS 2014 97.1 0.0 6,211 15-49 2,596 37 2,811 1,077 
Benin BEN STEPS 2015 98.6 3.5 2,702 18-69 1,273 36 1,987 5,910 
Kenya KEN STEPS 2015 95.0 0.3 2,681 18-69 1,197 37 2,798 26,452 
Zimbabwe ZWE DHS 2015 96.2 0.0 9,481 15-49 4,211 37 2,509 7,662 
South 
Africa 
ZAF DHS 2016 83.1 0.4 5,939 15-95 2,014 38 12,246 29,699 
Sudan SDN STEPS 2016 95.0 8.2 4,606 18-69 2,143 37 4,357 21,425 
Total NA NA NA 93.8 (86.2 
– 96.8)i 












Abbreviations: y, years; GDP, Gross Domestic Product; int. $, constant 2011 international dollars; NA, not available. CAMDI, Central America Diabetes Initiative; DHS, Demographic Health 
and Surveillance Survey39; EHS, European Health Survey; ENFR, Encuesta Nacional de Factores de Riesgo; ENS, Encuesta Nacional de Salud; ENSA, Encuesta Nacional de Salud; 
FESAL, Encuesta Nacional de Salud Familiar; ENSANUT, Encuesta Nacional de Salud y Nutrición; ENDSSR, Encuesta Nacional de Demografía y Salud Sexual y Reproductiva; ENDESA, 
Encuesta Nicargaüense de Demografía y Salud; IFLS-5, Indonesia Family Life Survey Wave 5; PNS, Pesquisa Nacional de Saúde; RHS, Reproductive Health Survey; SAGE, Study on 
global AGEing and adult health; SISS, Social Indicator Sample Survey; SOSAS, Surgeons OverSeas Assessment of Surgical need; STEPS, STEPwise approach to Surveillance. 
a Values are unweighted (i.e., do not account for the multi-stage cluster sampling used by the included surveys). 
b Sample size, median age, and age range are shown for those with a non-missing outcome variable. 
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c Year(s) in which the data collection for the survey was carried out. 
d This is the women’s response rate. 
e This is the percent of female participants who had a missing response for the survey question assessing whether she had ever undergone a screening test for cervical cancer.  
f This is GDP per capita in constant 2011 international dollars (as estimated by the World Bank17) for the year of the survey’s data collection. In case of a multi-year data collection period, 
we calculated the mean GDP per capita in constant 2011 international dollars across years. 
g Population in 2019 as estimated by United Nations, Population Division, Department of Economic and Social Affairs (2019).19 
h This is the combined number of Lebanese citizens and Syrian refugees living in Lebanon in 2017 as estimated by the UN Refugee Agency (UNHCR).40  
i This is the median value and interquartile range with each country having the same weight. 
j This is the sum across all countries. 
